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Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic familiar disease characterized by high incidence 
of sudden cardiac death (SCD) in young people with normal basal electrocardiogram and structurally normal heart. Treatment is based mainly in the 
use of beta-blockers, although there is controversy on its long-term effectiveness, needs for titration and follow-up. We discovered a family with more 
than 1400 members with high incidence of SCD in Gran Canaria (Spain). After a genetic screening, 179 alive carriers of a RyR2 mutation (G357S) 
were identified.
methods: A clinical protocol of treatment and follow-up was offered to all family members, based in exercise stress tests (ET) every 3 months, with 
an objective of maximum heart rate less than theoretical 80% and the absence of ventricular arrhythmias, increasing or changing betablockers to 
achieve it. If the carrier constantly failed to achieve the goal, an Implantable cardioverter defibrillator (ICD) was proposed.
results: After more than 4 years of application of the Protocol no SCD or cardiac arrests have occurred into this group. However, 3 events occurred 
between those that refused to be genotyped -53 potential carriers- (Figure)./
conclusions: The Protocol based on seriated ET to titrate Betablockers is useful and effective in management of CPVT, and should be 
recommended to carriers of a CPVT-related mutation and, probably, to all CPVT patients.
 
